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Abstract
In recent years, Serratia marcescens has emerged as an important agent of hospital- acquired infections, such as pneumonia, 
urinary tract infection, septicaemia and meningitis, particularly in vulnerable patients. Compared to Klebsiella pneumoniae 
and Escherichia coli, S. marcescens is less commonly associated with bla
KPC
 genes, yet few cases of plasmid transmission at 
the gastrointestinal level from K. pneumoniae carbapenemase (KPC)- producing Enterobacterales to S. marcescens have been 
described. Here we report a case of in vivo acquisition, during a 3- month period of hospitalization in the intensive care unit, of 
a bla
KPC-3
 gene carried by a pKpQIL- IT plasmid, and its probable transmission at the bronchial level among different species of 
Enterobacterales, including K. pneumoniae and S. marcescens. By using whole genome sequence analyses we were able provide 
insight into the dynamics of carbapenem- resistance determinants acquisition in the lower respiratory tract, a novel anatomical 
region for such plasmid transmission events, that usually involve the gastrointestinal tract. The co- presence at the same time 
of both wild- type and resistant Enterobacterales could have been the critical factor leading to the spread of plasmids harbouring 
carbapenem- resistance genes, of particular importance during surveillance screenings. The possibility of such an event may 
have significant consequences in terms of antimicrobial treatment, with a potential limitation of therapeutic options, thereby 
further complicating the clinical management of high- risk critically ill patients.
Serratia marcescens has traditionally been regarded as an 
opportunistic pathogen, as it tends to colonize the respiratory 
and urinary tracts [1]. However, in recent years a growing 
amount of evidence has demonstrated that it has effectively 
adapted to hospital environments, and has emerged as an 
important agent of hospital- acquired infections such as pneu-
monia, urinary tract infections, septicaemia and meningitis, 
particularly in vulnerable populations [2].
Like other members of Enterobacterales, S. marcescens carries 
both chromosomal and plasmid- mediated resistance determi-
nants for several antimicrobial agents, including beta- lactams 
and colistin. Compared to Klebsiella pneumoniae and Escheri-
chia coli, the acquisition of carbapenem- hydrolysing activity 
by plasmid blaKPC gene trasmission in S. marcescens has rarely 
been described. Nevertheless, when the transmission from 
K. pneumoniae carbapenemase (KPC)- producing Enterobac-
terales to S. marcescens was documented, it occurred at the 
gastrointestinal level [3–7].
However, colonization by Enterobacterales at the respiratory 
level in critically ill hospitalized patients could lead to alterna-
tive localization for transmission of resistance determinants. 
In the respiratory tract, having a resident flora susceptible to 
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resistance acquisition, especially if associated with recurrent 
bacteraemia, as in S. marcescens [8], could complicate the 
clinical management and surveillance of critically ill patients, 
mainly in intensive care units (ICUs). In this regard, our 
case report retrospectively describes the in vivo acquisition 
of a blaKPC-3 gene carried by a pKpQIL- IT plasmid and its 
probable transmission among different species of Enterobac-
terales, including S. marcescens, at the bronchial level in a 
single patient, during a 3- month ICU hospitalization. This 
is a non- interventional case report, and the clinical manage-
ment of the patient presented here corresponded to standard 
hospital clinical practice. Medical records were registered and 
processed by using pseudoanonymization measures, ensuring 
that it did not (and no longer) permit the identification of 
data subjects. According to the applicable relevant national 
legislation and local rules, specific informed consent was not 
mandatory.
On day 0, an adult man was admitted to the Emergency 
Room for haemorrhagic shock, pleural effusion and severe 
kidney injures due to stab wounds. Fig. 1 shows the timeline 
progression of the patient’s clinical history with indications 
of most relevant collected samples, and all administered 
therapy. After intensive abdominal surgical procedures 
(duodeno- colico laparotomy, right nephrectomy, hepatic 
haemostasis, duodenal and diaphragmatic lesion repair), he 
was transferred to the ICU. Upon ICU admission, surveil-
lance screening on selective chromogenic medium (chromID 
CARBA; bioMérieux) for nasal, pharyngeal (eSwab; Copan) 
or rectal (fecalSwab; Copan) colonization by carbapenem- 
resistant Enterobacterales (CRE) was negative, and the 
patient was thus started on treatment with ceftazoline and 
metronidazole.
On day 3, the patient was in septic shock and multi- organ 
failure. Microbiological cultures from the abdominal surgical 
wound, which appeared largely necrotic, led to the isolation 
of an S. marcescens strain (isolate S1) that was also detected 
in blood 1 day later (isolate S2). Identification of microor-
ganisms was performed by matrix- assisted laser desorption 
ionization- time of flight (MALDI- TOF) MS with MALDI 
Biotyper system (Bruker Daltonics).
Susceptibility profiles of both isolates (MicroScan WalkA-
wayPlus automated system; Beckman Coulter) were iden-
tical. MIC values according to EUCAST v.7.1 breakpoints 
Fig. 1. Timeline clinical history of the case patient. All surgical procedures performed during hospitalization in the ICU (grey circles), along 
with results of microbiological surveillance (dotted or striped circles) and blood cultures (black circles), frequency of septic shock episodes 
and full antibiotic treatment history are reported. Periods of antibiotic treatment discontinuation are reported as 'STOP'. All relevant 
isolated microorganisms are reported. ERCP, endoscopic retrograde cholangiopancreatography; EGDS, oesophagogastroduodenoscopy; 
ICU, intensive care unit; KPC- Ec, Klebsiella pneumoniae carbapenemase – Escherichia coli; KPC- Kp, Klebsiella pneumoniae carbapenemase 
– Klebsiella pneumoniae; N, negative.
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(http://www. eucast. org/ clinical_ breakpoint/) revealed that 
both strains S1 and S2 had reduced susceptibility to aztre-
onam (MIC=16 µg ml−1), ceftazidime (MIC>16 µg ml−1) 
and piperacillin- tazobactam (MIC=64 µg ml−1), but were 
susceptible to amikacin (MIC≤8 µg ml−1), ciprofloxacin 
(MIC≤0.5 µg ml−1), gentamicin (MIC≤2 µg ml−1), ertap-
enem (MIC≤0.5 µg ml−1), imipenem and meropenem 
(MIC≤1 µg ml−1).
After therapy adjustment to levofloxacin, tazocin, meropenem 
and tigecycline, follow- up blood culture yielded no microbial 
growth. Yet, during the following 2 months of ICU stay, the 
patient experienced repeated dehiscence of intestinal anas-
tomosis that required surgical re- interventions, along with 
multiple episodes of septic shock, and consequent adjust-
ments to his antibiotic treatment (Fig. 1).
Surveillance screening for rectal and/or respiratory coloniza-
tion was persistently negative until day 23, when an S. marces-
cens isolate (S3) was recovered from a respiratory sample, and 
a K. pneumoniae strain (K1) was isolated from a rectal swab. 
The S. marcescens S3 isolate showed no evidence of genetic 
resistance to carbapenems, and a phenotypic profile that was 
identical to previous abdominal (S1) and blood (S2) isolates.
On the other hand, the K1 strain was a KPC- producing K. 
pneumoniae (KPC- Kp; Table 1), as determined by GeneX-
pert CARBA- R assay (Cepheid). This rectal colonization 
by KPC- Kp persisted through the entire ICU stay, and was 
further complicated by the isolation of a KPC- producing E. 
coli (KPC- Ec, E1) on day 59.
At the respiratory level, simultaneous colonization by KPC- Kp 
(K2, K4 and K5 isolates) and S. marcescens (S5, S6 and S8) 
strains was detected after day 51. Notably, before respiratory 
colonization by KPC- Kp occurred, the S. marcescens strain 
recovered at this level (S3) was fully susceptible to carbap-
enems. By contrast, isolate S5 started to show reduced sensi-
tivity against ertapenem, and a week later the S6 S. marcescens 
strain was also resistant to imipenem (Table 1 and Fig. 1).
No evidence of systemic dissemination of this KPC- producing 
S. marcescens was found in our patient, as in all positive blood 
cultures S. marcescens strains presented the same phenotypic 
Table 1. Phenotypic and genetic features of clinical isolates found in the case patient
Isolate ID Isolated bacteria Days of stay in 
ICU
Specimen type Carbapenems MIC (µg ml−1) Whole genome sequencing
ERT IMP MER Carbapenemase/ESBL genes Resistance determinants
S1 S. marcescens 3 Surgical wound 
pus
≤0.5 ≤1 ≤1 Not performed
S2 S. marcescens 4 Blood culture ≤0.5 ≤1 ≤1 None tet41, aac(6’)- Ib- cr
S3 S. marcescens 23 Bronchial 
aspirate
≤0.5 ≤1 ≤1 Not performed
K1 K. pneumoniae 23 Rectal swab >1 >8 4 blaKPC-3, blaOXA-9, blaTEM- 1D, 
blaSHV-11
aac (6)- Ib, oqxA, oqxBgb
S4 S. marcescens 46 Blood culture ≤0.5 ≤1 ≤1 None tet41, aac(6’)- Ib- cr
K2 K. pneumoniae 51 Bronchial 
aspirate
>1 >8 >8 blaKPC-3, blaOXA-9, blaTEM- 1D, 
blaSHV-11
aac (6)- Ib, oqxA, oqxBgb
S5 S. marcescens 51 Bronchial 
aspirate
>1 ≤1 ≤1 None tet41, aac(6’)- Ib- cr
K3 K. pneumoniae 59 Rectal swab >1 >8 4 Not performed
E1 E. coli 59 Rectal swab >1 4 4 blaKPC-3, blaOXA-9, blaTEM- 1D sul1, aadA5, dfrA17
K4 K. pneumoniae 59 Bronchial 
aspirate
>1 >8 >8 Not performed
S6 S. marcescens 59 Bronchial 
aspirate
>1 >8 2 blaKPC-3, blaOXA-9, blaTEM- 1D tet41, aac(6’)- Ib- cr
S7 S. marcescens 66 Venous catheter 
pus
>1 >8 2 blaKPC-3, blaOXA-9, blaTEM- 1D tet41, aac(6’)- Ib- cr
S8 S. marcescens 68 Bronchial 
aspirate
>1 >8 ≤1 Not performed
K5 K. pneumoniae 68 Bronchial 
aspirate
>1 >8 >8 Not performed
ERT, ertapenem; ESBL, extended- spectrum β-lactamase; ICU, intensive care unit; IMP, imipenem; MER meropenem; MIC, minimum inhibitory 
concentration.
85
Bielli et al., Journal of Medical Microbiology 2020;69:82–86
profile to the first S1 isolate, fully susceptible to carbapenems 
(Table 1). On day 66, a KPC S. marcescens strain (S7) was 
isolated in a venous catheter sample, but its recovery was 
not related to any systemic clinical manifestation during 
follow- up.
After 3 months from admission, the patient was discharged 
from the ICU in stable clinical conditions, with no ongoing 
septic events.
To better clarify the transmission dynamics of carbapenem 
resistance, the S. marcescens isolates from blood (S2, S4), 
bronchial aspirate (S5, S6) and venous catheter (S7) samples, 
as well as the KPC- Kp (K1, K2) and KPC- Ec (E1) strains were 
analysed by whole genome sequencing (WGS), performed 
with the Illumina MiSeq platform. Briefly, 1 ng of total DNA 
extracted using the DNeasy Blood and Tissue kit (Qiagen) was 
processed using the Nextera XT kit and the obtained library 
pool was loaded on an Illumina MiSeq sequencer running 
250 bp paired- end reads (Illumina). The reads were assembled 
by the SPAdes Genome Assembler [9] and antibiotic resistance 
genes were identified using SRST2 [10] and ARG- ANNOT 
[11] databases. Multilocus sequence typing (MSLT) profiles 
were determined in silico: for K. pneumoniae using gene vari-
ants retrieved from BIGSdb (http:// bigsdb. pasteur. fr/ kleb-
siella/ klebsiella. html) and for E. coli using the Wirth scheme 
(https:// enterobase. warwick. ac. uk/ species/ ecoli/ allele_ st_ 
search). For each S. marcescens isolate the reads were aligned 
against the Db11 reference strain (GCA_000513215.1) and 
single nucleotide polymorphisms (SNPs) were called using 
the GATK best practice procedure [12]. For CoreSNP calling, 
the reference genome regions including repeats or phages, 
identified using MUMmer [13] and PhiSpy [14] respectively, 
were masked. The obtained CoreSNP alignment was then 
subjected to maximum- likelihood (ML) phylogenetic analysis 
using RaxML8 software [15], after best model identification 
performed using ModelTest- NG [16]. A phylogenetic recon-
struction with RaxML8 software was also performed for the 
K1 and K2 K. pneumoniae isolates.
Phylogenetic analysis showed that all sequenced S. marces-
cens isolates except S2, the first collected from blood culture, 
clustered together (data not shown). Isolate S2 differed by 
435–444 SNPs from the other strains, which instead showed 
a maximum distance of 10 SNPs among each other. This 
supported the spread of a single bacterial strain, either 
acquired after S2 isolation, or present as a mixed clone in the 
original S. marcescens population, not initially isolated but 
subsequently becoming dominant.
By contrast, both KPC- Kp from rectal (K1) and respiratory 
(K2) specimens were clonally related and were of ST512, 
while the KPC- Ec strain (E1) belonged to ST69, a well- known 
extra- intestinal pathogenic clone.
All S. marcescens isolates harboured tet41 and aac(6')- Ib- cr 
resistance genes, again supporting a common genetic back-
ground. However, the S6 (brochial aspirate) and S7 (venous 
catheter) strains that showed phenotypic resistance to carbap-
enems also presented the blaKPC-3, blaOXA-9 and blaTEM- 1D genetic 
determinants, the same as detected in KPC- Kp and KPC- Ec. 
Using the PlasmidFinder database (https:// cge. cbs. dtu. dk/ 
services/ PlasmidFinder/), an IncFIB_pQil plasmid showing 
>99 % identity to plasmid pKpQIL- IT (accession number 
JN233705) was found in all KPC- producing isolates. No plas-
mids were detected in carbapenem- susceptible S. marcescens 
strains.
Co- infections with various carbapenem- resistant strains of 
Gram- negative species represent a critical point in clinical 
microbiology, as movement of plasmids and other mobile 
genetic elements may also occur at the inter- species level, 
including K. pneumoniae and S. marcescens [6]. Although 
this is well known, the majority of these data are generally 
linked to transmission occurring within the gastrointestinal 
tract.
In our patient, the sequence of microbiological evidence 
suggests that the patient initially acquired a KPC- producing 
K. pneumoniae in the gastrointestinal tract, but the transmis-
sion of the resistant plasmid actually occurred in the lower 
respiratory tract. Indeed, the lack of such plasmidic genetic 
determinants (blaKPC-3, blaOXA-9, blaTEM- 1D) in the first bronchial 
S. marcescens isolate (S5), and the subsequent development of 
blaKPC-3- related carbapenem resistance in the second bronchial 
isolate (S6), after co- localization with a blaKPC-3- producing 
KPC- Kp harbouring a plasmid with the same incompatibility 
group, suggests strongly the inter- species transmission of this 
form of drug resistance at the respiratory level. Although not 
conclusively demonstrated, because we did not evaluate the 
transconjugant clones by conjugational transfer experiments 
[7], this hypothesis is further supported by the strict phyloge-
netic relatedness of strains S5 and S6, excluding the respira-
tory acquisition of a second, KPC- producing, S. marcescens 
strain during hospitalization.
Although the presence of respiratory colonization did not 
lead to episodes of bacteraemia by carbapenem- resistant S. 
marcescens in our patient, the recovery of a blaKPC-3- producing 
strain at the level of the venous catheter, closely related phylo-
genetically to the bronchial population, supports the tendency 
of this bacterium to extend colonization also outside the lower 
respiratory tract. As S. marcescens already has intrinsic resist-
ance to several antimicrobial agents, including some classes 
of beta- lactams and tetracyclines, quinolones and amino-
glycosides, the possible acquisition of plasmids harbouring 
carbapenem- resistance genes within multiple anatomical 
reservoirs may further limit the therapeutic options to treat 
this pathogen, with potentially crucial consequences, espe-
cially in critically ill patients.
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